Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Balcinrenone/dapagliflozin - AstraZeneca

Next Previous
Drug Profile

Balcinrenone/dapagliflozin - AstraZeneca

Alternative Names: Dapagliflozin/balcinrenone - AstraZeneca

Latest Information Update: 18 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Acetamides; Anti-ischaemics; Antihyperglycaemics; Antivirals; Benzhydryl compounds; Benzoxazines; Cardiovascular therapies; Chlorobenzenes; Fluorinated hydrocarbons; Glucosides; Heart failure therapies; Hepatoprotectants; Ketones; Obesity therapies; Phenyl ethers; Pyrans; Small molecules; Toluenes; Urologics
  • Mechanism of Action Mineralocorticoid receptor modulators; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Heart failure; Renal failure

Most Recent Events

  • 06 Aug 2026 AstraZeneca initiates enrolment in a phase I trial for Renal failure (Treatment-experienced) in USA (PO) (NCT07754331)
  • 05 Aug 2026 AstraZeneca plans a phase I trial for Renal failure in the US (PO) (NCT07754331)
  • 03 Jun 2026 AstraZeneca plans the phase III BalanceD-CKD trial for Chronic kidney disease in Argentina, Canada, Germany, Japan, Poland, South Korea, Taiwan, Vietnam (PO), in September 2026 (NCT07624305) (EUCT2026-526114-90-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top